Skip to main content

Peer Review reports

From: Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy

Original Submission
5 Apr 2016 Submitted Original manuscript
1 Dec 2016 Reviewed Reviewer Report - Todd Miller
27 Dec 2016 Author responded Author comments - Seung Kim
Resubmission - Version 2
27 Dec 2016 Submitted Manuscript version 2
29 Jan 2017 Author responded Author comments - Seung Kim
Resubmission - Version 3
29 Jan 2017 Submitted Manuscript version 3
4 Mar 2017 Author responded Author comments - Seung Kim
Resubmission - Version 4
4 Mar 2017 Submitted Manuscript version 4
Publishing
14 Mar 2017 Editorially accepted
23 Mar 2017 Article published 10.1186/s12885-017-3196-6

You can find further information about peer review here.

Back to article page